石药集团瑞戈非尼片获药监局药品注册批件
财中社1月20日电石药集团（01093）发布公告，本集团开发的瑞戈非尼片（40mg）已获得中华人民共和国国家药品监督管理局颁发的药品注册批件，并视同通过仿制药质量和疗效一致性评价。瑞戈非尼是一种小分子口服多靶点激酶抑制剂，适用于多种癌症患者，包括转移性结直肠癌、局部晚期胃肠道间质瘤和肝细胞癌患者。
该产品的获批将进一步丰富公司的抗肿瘤领域产品线，增强公司的市场竞争力。此公告标志着公司在药品研发方面取得了重要进展。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10